Comparative Pharmacology
Head-to-head clinical analysis: EVOXAC versus MYOTONACHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOXAC versus MYOTONACHOL.
EVOXAC vs MYOTONACHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.
Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.
30 mg orally three times daily.
25 mg orally three times daily. Maximum dose 100 mg four times daily.
None Documented
None Documented
The terminal elimination half-life is approximately 1 hour. Due to its short half-life, multiple daily dosing is required for sustained pharmacological effect.
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment).
Approximately 50% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion; the remaining 50% is metabolized by ester hydrolysis and excreted as inactive metabolites in urine.
Renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist